LT2807165T - Pirimido[4,5-b]indolo dariniai ir jų panaudojimas kraujodaros kamieninių ląstelių dauginime - Google Patents

Pirimido[4,5-b]indolo dariniai ir jų panaudojimas kraujodaros kamieninių ląstelių dauginime

Info

Publication number
LT2807165T
LT2807165T LTEP13740815.9T LT13740815T LT2807165T LT 2807165 T LT2807165 T LT 2807165T LT 13740815 T LT13740815 T LT 13740815T LT 2807165 T LT2807165 T LT 2807165T
Authority
LT
Lithuania
Prior art keywords
haircle
pyrimide
reproduction
indole derivatives
indole
Prior art date
Application number
LTEP13740815.9T
Other languages
English (en)
Lithuanian (lt)
Inventor
Guy Sauvageau
Yves Gareau
Réjean RUEL
Stéphane GINGRAS
Iman FARES
Original Assignee
Université de Montréal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48872865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2807165(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université de Montréal filed Critical Université de Montréal
Publication of LT2807165T publication Critical patent/LT2807165T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEP13740815.9T 2012-01-27 2013-01-25 Pirimido[4,5-b]indolo dariniai ir jų panaudojimas kraujodaros kamieninių ląstelių dauginime LT2807165T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261591521P 2012-01-27 2012-01-27
PCT/CA2013/050052 WO2013110198A1 (en) 2012-01-27 2013-01-25 Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells

Publications (1)

Publication Number Publication Date
LT2807165T true LT2807165T (lt) 2019-07-25

Family

ID=48872865

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13740815.9T LT2807165T (lt) 2012-01-27 2013-01-25 Pirimido[4,5-b]indolo dariniai ir jų panaudojimas kraujodaros kamieninių ląstelių dauginime

Country Status (24)

Country Link
US (3) US9409906B2 (enExample)
EP (1) EP2807165B1 (enExample)
JP (1) JP6250556B2 (enExample)
KR (1) KR102098122B1 (enExample)
CN (1) CN104144931B (enExample)
AU (1) AU2013212457B2 (enExample)
BR (1) BR112014018524B1 (enExample)
CA (1) CA2862140C (enExample)
CY (1) CY1121799T1 (enExample)
DK (1) DK2807165T3 (enExample)
ES (1) ES2733946T3 (enExample)
HR (1) HRP20191189T1 (enExample)
HU (1) HUE044070T4 (enExample)
IL (1) IL233587B (enExample)
LT (1) LT2807165T (enExample)
NZ (1) NZ627188A (enExample)
PL (1) PL2807165T3 (enExample)
PT (1) PT2807165T (enExample)
RS (1) RS59002B1 (enExample)
SG (1) SG11201404241SA (enExample)
SI (1) SI2807165T1 (enExample)
SM (1) SMT201900360T1 (enExample)
TR (1) TR201909582T4 (enExample)
WO (1) WO2013110198A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102098122B1 (ko) 2012-01-27 2020-04-07 유니버시떼 드 몬트리얼 피리미도[4,5-b]인돌 유도체 및 조혈 줄기 세포의 증식에서의 이의 용도
JP6401773B2 (ja) * 2013-03-11 2018-10-10 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法
US9757378B2 (en) 2013-05-17 2017-09-12 Universite De Montreal Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
EP3110818B1 (en) * 2014-02-28 2019-10-23 The Regents of The University of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
CN106414445B (zh) * 2014-04-22 2020-07-03 蒙特利尔大学 化合物及其在扩增造血干细胞和/或造血祖细胞中的应用
CN107208111B (zh) * 2014-09-18 2021-07-06 蒙特利尔大学 用于增强病毒基因转移至人造血细胞的化合物和方法
EA201791443A1 (ru) * 2014-12-31 2018-01-31 Антродженезис Корпорейшн Естественные киллерные клетки и их применения
WO2016118780A1 (en) * 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
JP6954844B2 (ja) * 2015-06-05 2021-10-27 エマ−ケベック 造血幹細胞を培養するため及び／又は造血幹細胞を前駆体へ分化させるための方法及びその使用
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN105316293A (zh) * 2015-09-23 2016-02-10 广东颐养抗衰老研究院 一种体外获得造血干/祖细胞的方法
JP2018535666A (ja) * 2015-10-15 2018-12-06 セルラリティ インコーポレイテッド ナチュラルキラー細胞およびｉｌｃ３細胞ならびにそれらの使用
US20190010495A1 (en) * 2015-12-28 2019-01-10 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
AU2017235461B2 (en) 2016-03-15 2023-02-23 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
JP2019519486A (ja) * 2016-05-07 2019-07-11 セルラリティ インコーポレイテッド ナチュラルキラー細胞を使用して急性骨髄性白血病および多発性骨髄腫を処置する方法
WO2018048346A1 (en) * 2016-08-18 2018-03-15 National University Of Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
EP3519577A1 (en) 2016-09-28 2019-08-07 Novartis AG Porous membrane-based macromolecule delivery system
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
KR20250107976A (ko) 2017-09-29 2025-07-14 인텔리아 테라퓨틱스, 인크. 지질 나노파티클을 이용한 mRNA 전달의 체외 방법
AU2018361971A1 (en) * 2017-11-03 2020-06-04 Universite De Montreal Compounds and use thereof in the expansion of stem cells and/or progenitor cells
US20200338132A1 (en) * 2018-01-03 2020-10-29 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
CA3091865A1 (en) 2018-02-20 2019-08-29 Universite De Montreal Expansion of nk and dc cells in vivo mediating immune response
ES2979163T3 (es) * 2018-10-31 2024-09-24 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
KR102329235B1 (ko) * 2018-11-21 2021-11-22 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
US20230073512A1 (en) * 2019-12-18 2023-03-09 Universite De Montreal Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds
WO2021123920A1 (en) 2019-12-18 2021-06-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
AU2020411454A1 (en) 2019-12-26 2022-07-14 Nextgem Inc. Method for culturing hematopoietic stem cells
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2021256977A1 (en) * 2020-06-15 2021-12-23 Subramaniam Agatheeswaran Novel methods and compounds for protein degradation
EP4171593A4 (en) * 2020-06-25 2024-07-03 Angiocrine Bioscience, Inc. Endothelial cells for mitigation of chemotherapy-induced toxicity
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
AU2021360590A1 (en) 2020-10-14 2023-06-15 Ossium Health, Inc. Systems and methods for extraction and cryopreservation of bone marrow
CN117279650A (zh) 2020-12-18 2023-12-22 奥瑟姆健康公司 细胞治疗方法
TW202309044A (zh) * 2021-04-26 2023-03-01 日商住友製藥股份有限公司 氧呯衍生物
WO2022232839A1 (en) 2021-04-30 2022-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improved production of primary cd34+ cells
US20250127809A1 (en) 2021-06-23 2025-04-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
GB202111169D0 (en) 2021-08-03 2021-09-15 Adaptimmune Ltd Methods of T cell production
CN114736862B (zh) * 2022-05-18 2024-05-28 诺航生物技术研究院徐州有限公司 一种造血干细胞培养基和造血干细胞的体外扩增方法
CN117164593A (zh) * 2023-08-31 2023-12-05 贵州省天然产物研究中心 一种嘧啶并吲哚类化合物及其制备方法和应用、抗红白血病药物
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
US11964981B1 (en) 2023-09-18 2024-04-23 King Faisal University Substituted pyrimido[4,5-b]indoles as CK2 inhibitors
CN117229284B (zh) * 2023-11-10 2024-02-06 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用
US12012414B1 (en) 2024-01-04 2024-06-18 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1262864A (en) * 1968-03-29 1972-02-09 Glaxo Lab Ltd Diazacarbazoles
JPH08502721A (ja) 1992-04-03 1996-03-26 ジ・アップジョン・カンパニー 医薬的に活性な二環式‐複素環アミン
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
DE69619114T2 (de) * 1995-07-06 2002-10-02 Novartis Ag, Basel Pyrolopyrimidine und verfahren zu ihrer herstellung
PT964865E (pt) 1997-01-08 2003-06-30 Upjohn Co Aminas triciclicas farmaceuticamente activas
JP2002529502A (ja) 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション 血小板減少症の治療法
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
AU4808300A (en) 1999-04-30 2000-11-17 Neurogen Corporation 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
AU4692400A (en) 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
EP1213965B1 (en) 1999-09-10 2006-01-18 Smithkline Beecham Corporation Thrombopoietin mimetics
ES2279769T3 (es) 1999-09-24 2007-09-01 Smithkline Beecham Corporation Mimeticos de trombopoyetina.
WO2001034585A1 (en) 1999-11-05 2001-05-17 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
JP2003515560A (ja) 1999-12-06 2003-05-07 スミスクライン・ビーチャム・コーポレイション トロンボポイエチン模倣物
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
CA2436288A1 (en) 2000-12-19 2002-06-27 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1370252A4 (en) 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin mimetics
WO2002089746A2 (en) 2001-05-09 2002-11-14 The University Of Louisville Research Foundation, Inc. Hematopoietic stem cell chimerism to treat autoimmune disease
EP1442039A1 (en) 2001-10-31 2004-08-04 Bayer HealthCare AG Pyrimido (4,5-b) indole derivatives
AU2003248630A1 (en) 2002-06-06 2003-12-22 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1581527A4 (en) 2002-12-13 2006-11-22 Smithkline Beecham Corp MIMETICS OF THROMBOPOIETINE
AU2003300522A1 (en) * 2002-12-27 2004-07-22 Bayer Healthcare Ag 4-phenyl-pyrimido (4,5-b) indole derivatives
SG150387A1 (en) 2003-05-02 2009-03-30 Insception Bioscience Inc Apparatus and methods for amplification of blood stem cell numbers
CA2542076C (en) 2003-10-14 2013-02-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors
JP2008539277A (ja) * 2005-04-28 2008-11-13 スーパージェン， インコーポレイテッド プロテインキナーゼインヒビター
BRPI0613460A2 (pt) 2005-07-14 2011-01-11 Irm Llc compostos e composições como inibidores de proteìna cinase
EP1749822B1 (en) * 2005-08-05 2008-10-15 Hybrigenics S.A. Novel cysteine protease inhibitors and their therapeutic applications
BRPI0616994A2 (pt) 2005-08-15 2011-07-05 Irm Llc compostos e composições como miméticos de tpo
WO2007145227A1 (ja) 2006-06-14 2007-12-21 Chugai Seiyaku Kabushiki Kaisha 造血幹細胞増加促進剤
JP2008050355A (ja) * 2006-08-21 2008-03-06 Eisai R & D Management Co Ltd 造血幹細胞を増殖、分化および／または循環系内に動員させる医薬組成物および方法
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
US20080207632A1 (en) * 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
EP2121692B1 (en) * 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
JP2010525836A (ja) * 2007-05-04 2010-07-29 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ヒト造血幹細胞のｅｘｖｉｖｏ増殖
EP2170886A1 (en) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
US7982035B2 (en) * 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
JP2010193879A (ja) * 2009-01-27 2010-09-09 Jms Co Ltd 臍帯血造血幹細胞の増殖制御方法およびその用途
WO2011056739A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Compounds and methods
EP2686320B1 (en) * 2011-03-15 2016-05-18 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors
KR102098122B1 (ko) 2012-01-27 2020-04-07 유니버시떼 드 몬트리얼 피리미도[4,5-b]인돌 유도체 및 조혈 줄기 세포의 증식에서의 이의 용도

Also Published As

Publication number Publication date
BR112014018524A2 (pt) 2021-06-08
ES2733946T3 (es) 2019-12-03
SI2807165T1 (sl) 2019-08-30
US20150011543A1 (en) 2015-01-08
PT2807165T (pt) 2019-07-12
US20170334904A1 (en) 2017-11-23
SG11201404241SA (en) 2014-08-28
AU2013212457B2 (en) 2017-02-16
BR112014018524B1 (pt) 2023-03-28
RS59002B1 (sr) 2019-08-30
KR20140121454A (ko) 2014-10-15
HK1203945A1 (en) 2015-11-06
JP6250556B2 (ja) 2017-12-20
US10336747B2 (en) 2019-07-02
CA2862140A1 (en) 2013-08-01
AU2013212457A1 (en) 2014-09-18
WO2013110198A1 (en) 2013-08-01
EP2807165A4 (en) 2015-08-26
TR201909582T4 (tr) 2019-07-22
PL2807165T3 (pl) 2019-09-30
IL233587B (en) 2019-11-28
IL233587A0 (en) 2014-08-31
HUE044070T4 (hu) 2019-12-30
CN104144931A (zh) 2014-11-12
EP2807165A1 (en) 2014-12-03
JP2015504902A (ja) 2015-02-16
US20160222017A1 (en) 2016-08-04
HRP20191189T1 (hr) 2019-10-04
CN104144931B (zh) 2018-04-10
NZ627188A (en) 2015-12-24
KR102098122B1 (ko) 2020-04-07
CY1121799T1 (el) 2020-07-31
EP2807165B1 (en) 2019-05-15
CA2862140C (en) 2020-04-21
US9409906B2 (en) 2016-08-09
HUE044070T2 (hu) 2019-09-30
DK2807165T3 (da) 2019-07-15
SMT201900360T1 (it) 2019-07-11
BR112014018524A8 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
LT2807165T (lt) Pirimido[4,5-b]indolo dariniai ir jų panaudojimas kraujodaros kamieninių ląstelių dauginime
HUE046216T2 (hu) 1H-pirazolo [3,4-b]piridin-származékok és terápiás alkalmazásuk
IL246311A0 (en) Pyrazolo[5,1-a]pyridine derivatives and methods of using them
LT3318565T (lt) Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
ZA201500970B (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
HUE053688T2 (hu) Biciklusos heterociklusos vegyületek és ezek terápiában történõ alkalmazása
ZA201503828B (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
LT2894151T (lt) Imidazolino dariniai, jų gamybos būdai ir jų naudojimas medicinoje
LT3083616T (lt) Bicikinių heterociklų junginiai ir jų panaudojimas terapijoje
CO7000778A2 (es) Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
PT2889298T (pt) Derivado de pirazolopirimidina substituído na posição 4 e suas utilizações em preparações farmacêuticas
EP2963013A4 (en) INDOLE AND AZAINDOLE DERIVATIVES HAVING AMPK ACTIVATION ACTIVITY EACH
PT2989105T (pt) Compostos de pirazino[1,2-a]indole, sua preparação e utilização em medicamentos
ZA201508613B (en) Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments
TH1401006251A (th) 1h-ไพราโซโล[3,4-b]ไพริดีนและการนำไปใช้ในการรักษาโรค